Evidence map›Paper›PMID 41826785›Full record

ArticleDrug delivery and translational research2026

Ginkgolide B-cyclodextrin inclusion complexes: an encapsulation strategy for improved solubility and aerosol inhalation therapy in bronchial asthma.

Yuying Wang, MingLi Wei, Yan Zhang, Yuxin Liu, Xiaoshuang Bi, Xingting Fan, Jingxin Gou, Haibing He, Xing Tang, Yu Zhang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuying Wang *School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
MingLi Wei *Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Yan ZhangSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, 110016, Liaoning Province, People's Republic of China.
Yuxin LiuDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Xiaoshuang BiDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Xingting FanSchool of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Jingxin GouDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Haibing HeDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Xing TangDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Yu ZhangDepartment of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 11016, Liaoning, China.
Tian YinSchool of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, 110016, Liaoning Province, People's Republic of China. yintianpharm@126.com.

Funding

Frontier Technology Platform Program of Educational Department of Liaoning Province LJ232410163022National Key R&D Program of China 2020YFE0201700National Natural Science Foundation of China 82172086
6 · The paper itself

Abstract

Bronchial asthma represents a long-term inflammatory reaction in the airways, marked by the accumulation of eosinophils. Ginkgolide B (GB), derived from ginkgo biloba, serves as a potent natural antagonist of platelet activating factor (PAF). It can greatly reduce the production and release of eosinophils while minimizing the infiltration of other inflammatory cells in the airways, thus contributing to the management of bronchial asthma. However, due to its low bioavailability caused by poor water solubility and inherent bitter taste, it's hard for Ginkgolide B to meet the standards required for effective treatment of asthma. In this study, we developed two cyclodextrin derivatives of Ginkgolide B, namely GB-SBE-β-CD and GB-HP-γ-CD, for the therapy of bronchial asthma through aerosol inhalation. Both SBE-β-CD and HP-γ-CD effectively capsulated the Ginkgolide B. Molecular docking analysis revealed the spatial structure of GB-SBE-β-CD and GB-HP-γ-CD, highlighting hydrogen bonding as the primary driving force behind their formation. In vitro cell assays demonstrated that both Ginkgolide B and Ginkgolide B-cyclodextrin inclusion compounds exhibited good safety and potent anti-inflammatory activity. In addition, inhalation of aerosolized GB-SBE-β-CD and GB-HP-γ-CD markedly alleviated the symptoms of OVA-induced asthma in BALB/c mice, lowering infiltration of inflammatory cells, and significantly contributing to asthma treatment. The current findings suggest that the inhalation of Ginkgolide B-cyclodextrin represents a safe and promising option for managing bronchial asthma.

Indexed as

Asthmabeta-Cyclodextrinsgamma-CyclodextrinsGinkgolidesLactonesAdministration, InhalationAerosolsAnimalsHumansMiceMice, Inbred BALB CMolecular Docking SimulationOvalbuminSolubilityAerosolsbeta-Cyclodextrinsgamma-Cyclodextrinsginkgolide BGinkgolideshydroxypropyl-gamma-cyclodextrinLactonesOvalbuminSBE4-beta-cyclodextrinBronchial asthmaCyclodextrinGinkgolide BInflammatory cell infiltrationNebulized inhalation

Identifiers

PMID41826785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.